Novo Nordisk Appoints New CEO, Cuts 2025 Sales Growth Target to 8-14% Amid U.S. Market Pressures
-
最新报道：Novo Nordisk has appointed a new CEO while revising its 2025 sales growth target downward to 8-14% due to increasing market pressures. The pharmaceutical giant, known for its diabetes and obesity treatments, made the leadership change as it faces heightened competition and pricing challenges in key markets. The reduced sales outlook reflects the company's cautious stance amid evolving healthcare regulations and reimbursement policies globally. Novo Nordisk remains committed to innovation in metabolic diseases but acknowledges the need for operational adjustments to maintain profitability.
下一篇
TRON Surges Past $0.32 After Nasdaq Listing as WeWake Leads Presale with Wallet-Free Onboarding
- TRON (TRX) gained 0.32% amid speculation about a potential Nasdaq listing, while WeWake le...
24小时热点
财联社10月26日电，也门胡塞武装宣布对沙特阿拉伯境内的多个目标发动了袭击，包括利雅得机场、位于海米斯穆谢特（Khamis Mushait）的空军基地，以及位于吉赞（Jazan）的海军基地
币界网消息，财联社10月26日电，也门胡塞武装宣布对沙特阿拉 ...
144
热点专题
413027